Developer docs
API playgroundTry for free, no card

Search company profiles

Aurobindo Pharma USA, Inc.

Full company profile

uuid000apes

Namestring
Aurobindo Pharma USA, Inc.
Legal namestring
Aurobindo Pharma USA, Inc.
Company typeenum
Private
Founded yearint
1994
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersEast Windsor, United States
HQ citystring
East Windsor
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, active pharmaceutical ingredients, oral solid formulations, generic drug distribution, contract pharmaceutical manufacturing
Industry4 codes
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical and Medicine Manufacturing32541
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Generic Pharmaceuticals Manufacturing
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Generic Pharmaceutical Sales
TypeOne Time License
Description

Revenue generated from manufacturing and selling generic pharmaceuticals including oral solids, topicals, injectables, ophthalmics, and inhalations. Products are sold to national wholesalers and retail chains.

aurobindousa.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Aurohealth
Description

Over the counter products division

aurobindousa.com
+3 more records
Core offering1 text field

Aurobindo Pharma USA manufactures and distributes a broad line of generic pharmaceutical products including oral solids, topicals, injectables, ophthalmics, and inhalations, supported by a vertically integrated supply chain that spans API production (17 facilities, 250+ API products), formulation, manufacturing, automated packaging, and warehousing/distribution (567,000 sq ft, 40,000 pallet capacity). The company sells exclusively through national wholesalers, retail pharmacy chains, and authorized distributors, and also markets branded specialty products such as oncology injectables through subsidiary Acrotech Biopharma and women's health products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 60 billion+ dosage forms manufactured in FY25
+2 more records
Product overview1 text field

Aurobindo Pharma USA is a generic pharmaceutical company offering a vertically integrated portfolio of over 225 product families including oral solids, topicals, injectables, ophthalmics, and inhalations. The portfolio spans therapeutic areas including antibiotics, antivirals, respiratory, hematology, cardiovascular, CNS, and women's health. The company operates 17 API facilities with over 250 API products on the market. Product lines include Aurovela oral contraceptives, HIV medications like Atazanavir, oncology injectables through subsidiary Acrotech Biopharma, and was developing the UB-612 COVID-19 vaccine with COVAXX. The company has approximately 60 billion dosage forms manufactured annually and serves 150 countries globally.

Product and service21 records
1Generic Pharmaceuticals Portfolio
CategoryGeneric Pharmaceuticals
Description

A broad line of AB-rated generic pharmaceutical finished dosage forms covering therapeutic categories such as antibiotics, antivirals, respiratory, hematology, cardiovascular, and central nervous system conditions, sold to national wholesalers and retail pharmacy chains.

2Active Pharmaceutical Ingredients (APIs)
CategoryActive Pharmaceutical Ingredients
Description

More than 250 active pharmaceutical ingredient products including anti-infectives, peptides, biosimilars, vaccines, and polymers, manufactured across 17 API facilities for internal formulation use and external customers.

3Aurovela Oral Contraceptives
CategoryWomen's Health / Oral Contraceptives
Description

Generic oral contraceptive product line marketed as AB-rated equivalents to Loestrin products, indicated for pregnancy prevention.

4Mili and Tri-Mili Oral Contraceptives
CategoryWomen's Health / Oral Contraceptives
Description

Oral contraceptive product line of AB-rated generic equivalents to Ortho Cyclen and Ortho Tri-Cyclen; Mili for pregnancy prevention and Tri-Mili additionally indicated for moderate acne vulgaris.

5Zumandimine and Lo-Zumandimine Oral Contraceptives
CategoryWomen's Health / Oral Contraceptives
Description

Oral contraceptive product line of AB-rated generic equivalents to YASMIN and YAZ; Lo-Zumandimine additionally indicated for premenstrual dysphoria disorder symptoms and moderate acne.

6Atazanavir Capsules
CategoryAntiretroviral / HIV
Description

AB-rated generic equivalent of REYATAZ atazanavir capsules available in 100 mg, 150 mg, 200 mg, and 300 mg strengths, indicated in combination with other antiretrovirals for HIV treatment.

7Sildenafil Citrate Tablets
CategoryMen's Health / Erectile Dysfunction
Description

AB-rated generic equivalent to VIAGRA sildenafil citrate tablets in 25 mg, 50 mg, and 100 mg strengths for the treatment of erectile dysfunction.

8Oncology Injectable Portfolio (Acrotech Biopharma)
CategoryBranded Oncology Injectables
Description

Branded specialty oncology injectable product portfolio (including Marqibo and Khapzory) held through wholly-owned subsidiary Acrotech Biopharma LLC, serving US specialty distribution channels for cancer treatment.

9UB-612 COVID-19 Vaccine
CategoryVaccines
Description

Multitope peptide-based COVID-19 vaccine candidate licensed from COVAXX for development, commercialization and manufacturing for India and UNICEF markets, with initial 220 million dose capacity.

10Cephalexin For Oral Suspension USP
CategoryGeneric Antibiotic / Oral Suspension
Description

AB-rated generic equivalent to Keflex for Oral Suspension in 125 mg/5 mL and 250 mg/5 mL strengths, indicated for respiratory tract infections, otitis media, skin/skin structure infections, bone infections, and genitourinary tract infections.

11Tofacitinib Tablets
CategoryGeneric Immunology / Rheumatology
Description

AB-rated generic equivalent to Xeljanz Tablets in 5 mg and 10 mg strengths, indicated for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

12Eluxadoline Tablets
CategoryGeneric Gastroenterology
Description

AB-rated generic equivalent to Viberzi Tablets in 75 mg and 100 mg strengths, indicated for irritable bowel syndrome with diarrhea (IBS-D).

13Canagliflozin Tablets
CategoryGeneric Antidiabetic (SGLT2 Inhibitor)
Description

AB-rated generic equivalent to Invokana Tablets in 100 mg and 300 mg strengths, indicated as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus.

14Pirfenidone Capsules USP
CategoryGeneric Respiratory / Antifibrotic
Description

AB-rated generic equivalent to Esbriet Capsules in 267 mg strength, indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

15Glycerol Phenylbutyrate Oral Liquid
CategoryGeneric Rare Disease / Metabolic
Description

AB-rated generic equivalent to Ravicti Oral Liquid at 1.1 grams per mL, indicated as a nitrogen-binding agent for the chronic management of urea cycle disorders (UCDs).

16Dapagliflozin Tablets
CategoryGeneric Antidiabetic (SGLT2 Inhibitor)
Description

AB-rated generic equivalent to Farxiga Tablets in 5 mg and 10 mg strengths, indicated as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus.

17Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
CategoryGeneric Antidiabetic (Combination)
Description

AB-rated generic equivalent to Xigduo XR Tablets available in four strengths, indicated as adjunct to diet and exercise for type 2 diabetes when both dapagliflozin and metformin are appropriate.

18Cefixime Capsules
CategoryGeneric Antibiotic / Cephalosporin
Description

AB-rated generic equivalent to Suprax Capsules in 400 mg strength, indicated for urinary tract infections, pharyngitis, acute exacerbations of chronic bronchitis, and uncomplicated gonorrhea.

19Clindamycin Phosphate Gel USP
CategoryGeneric Dermatological / Topical Antibiotic
Description

AB-rated generic equivalent to Cleocin T Gel at 1% strength, indicated for the topical treatment of acne vulgaris.

20Citalopram Capsules
CategoryGeneric CNS / Antidepressant
Description

AB-rated generic equivalent of Citalopram Capsules in 30 mg strength, indicated for the treatment of Major Depressive Disorder (MDD) in adults.

21Siponimod Tablets
CategoryGeneric Neurology / Multiple Sclerosis
Description

AB-rated generic equivalent to Mayzent Tablets in 0.25 mg, 1 mg, and 2 mg strengths, indicated for the treatment of relapsing forms of multiple sclerosis.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-12-24
Description

Aurobindo Pharma entered exclusive license agreement with COVAXX to develop, commercialize and manufacture UB-612 COVID-19 vaccine for India and UNICEF. Aurobindo has capacity to manufacture 220 million doses initially with plans to expand to 480 million doses by June 2021. UB-612 is the first multitope peptide-based vaccine candidate.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Aurobindo became partner to Dispensary of Hope in 2012. In 5 years, donated 3,736,413 doses of medicine. Donated products distributed to federally qualified health centers, free clinics, charitable pharmacies serving uninsured patients at or below 200% of Federal Poverty Guidelines.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Partnership from 2013-2016 provided critically needed medicines to qualified healthcare institutions for over 333,000 patients globally, including Dominican Republic, Uganda, and Malawi. Medicines treated infectious and chronic diseases including bacterial infections, diabetes, hypertension, migraine, and depression.

4Brother's Brother Foundation
Strategic tierCoreTypeGTM or Marketing Partner
Description

Ongoing support of Brother's Brother Foundation for life-saving treatments. Pharmaceuticals donated to continents across 19 countries including Guatemala, Haiti, Ghana, Nigeria, Philippines, Uganda, Dominican Republic, Cameroon, Peru, Nicaragua, Honduras, Costa Rica, Malawi, Kenya, Central African Republic, India, Panama, Ecuador, and Vietnam.

careers.aurobindousa.com
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

FTC-approved acquisition of Lannett Company LLC for $250 million cash-free, debt-free transaction. Adds Seymour, Indiana manufacturing facility with approximately 4 billion doses annual capacity. Expands portfolio in complex generics and non-opioid controlled substances. Expected to close June 2026.

Strategic tierMinorTypeOthers
Description

As condition of FTC approval for Lannett acquisition, Aurobindo required to divest four generic pharmaceutical products to Quagen Pharmaceuticals to prevent market power consolidation in specific drug markets.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Acrotech Biopharma LLC, wholly-owned subsidiary of Aurobindo Pharma USA, acquired portfolio of seven branded oncology injectable products from Spectrum Pharmaceuticals. Transaction valued at $160 million upfront plus up to $140 million in milestones. Expected to generate $100 million revenue in first 12 months.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Endo International
TypeBroad incumbent
Description

Specialty and generics pharmaceutical company with US-focused operations across sterile injectables, generics, and branded specialty products. Comparable in US distribution and complex generics ambitions similar to Aurobindo's Lannett integration plans.

TypeDirect peer
Description

The world's largest generic pharmaceutical manufacturer with an extensive US generics portfolio across oral solids, injectables, and specialty categories. Teva competes head-to-head with Aurobindo in distributing generic pharmaceuticals to US wholesalers and retail chains.

TypeDirect peer
Description

India-headquartered generics and biosimilars manufacturer with a US commercial presence. Comparable in product mix (oral solids, injectables, biosimilars), India-to-US integration, and ANDA-driven revenue model.

TypeDirect peer
Description

Major India-based generic pharmaceutical manufacturer with US operations and a broad portfolio of oral solids, injectables, and respiratory medications. Comparable as another vertically integrated Indian generic exporter serving the US market.

5Sun Pharmaceutical Industries
TypeDirect peer
Description

India-based global generic pharmaceutical company with a large US subsidiary (Sun Pharma Global FZE / Taro). Comparable to Aurobindo as an Indian-headquartered generic exporter with US FDA-approved manufacturing and broad US distribution through wholesalers.

TypeDirect peer
Description

India-headquartered generic manufacturer with significant US presence in oral solids, injectables, and complex generics. Comparable to Aurobindo in targeting ANDA-rich therapeutic areas and supplying US national wholesalers.

7Sandoz (Novartis)
TypeDirect peer
Description

Global leader in off-patent medicines, including generics and biosimilars, with a major US generics business across oral solids, injectables, and complex generics. Directly comparable to Aurobindo's vertically integrated generics model and ANDA-driven US growth strategy.

TypeDirect peer
Description

India-headquartered pharmaceutical company with US generics business and a vertically integrated API-to-finished-dose manufacturing model. Comparable in geographic origin, product mix, and ANDA-driven US growth strategy.

TypeDirect peer
Description

Large diversified generics and specialty manufacturer with significant US footprint across oral solids, injectables, and complex generics. Viatris's broad portfolio, ANDA pipeline, and national wholesaler relationships mirror Aurobindo's competitive position in the US market.

TypeDirect peer
Description

Canadian-based privately held generic pharmaceutical manufacturer with a substantial US generics business. Comparable as a privately held, vertically integrated generics competitor distributing through US wholesalers and retail chains.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aurobindo Pharma USA, Inc.

Generic Pharmaceuticals Manufacturingaurobindousa.com

Aurobindo Pharma USA, Inc. firmographics

Firmographics
Name
Aurobindo Pharma USA, Inc.
Legal name
Aurobindo Pharma USA, Inc.
Website
https://aurobindousa.com
Company type
Private
Founded year
1994
Operating status
Operating
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

Aurobindo Pharma USA, Inc. industry classification

Industry
Product category
Generic Pharmaceuticals Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics

Keywords

  • Generic pharmaceuticals
  • Active pharmaceutical ingredients
  • Oral solid formulations
  • Generic drug distribution
  • Contract pharmaceutical manufacturing

Where Aurobindo Pharma USA, Inc. is headquartered

Location

Headquarters

HQ city
East Windsor
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Aurobindo Pharma USA, Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Generic Pharmaceutical Sales: Revenue generated from manufacturing and selling generic pharmaceuticals including oral solids, topicals, injectables, ophthalmics, and inhalations. Products are sold to national wholesalers and retail chains.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Aurobindo Pharma USA, Inc. product offering

Product offering

Core offering

Aurobindo Pharma USA manufactures and distributes a broad line of generic pharmaceutical products including oral solids, topicals, injectables, ophthalmics, and inhalations, supported by a vertically integrated supply chain that spans API production (17 facilities, 250+ API products), formulation, manufacturing, automated packaging, and warehousing/distribution (567,000 sq ft, 40,000 pallet capacity). The company sells exclusively through national wholesalers, retail pharmacy chains, and authorized distributors, and also markets branded specialty products such as oncology injectables through subsidiary Acrotech Biopharma and women's health products.

Product overview

Aurobindo Pharma USA is a generic pharmaceutical company offering a vertically integrated portfolio of over 225 product families including oral solids, topicals, injectables, ophthalmics, and inhalations. The portfolio spans therapeutic areas including antibiotics, antivirals, respiratory, hematology, cardiovascular, CNS, and women's health. The company operates 17 API facilities with over 250 API products on the market. Product lines include Aurovela oral contraceptives, HIV medications like Atazanavir, oncology injectables through subsidiary Acrotech Biopharma, and was developing the UB-612 COVID-19 vaccine with COVAXX. The company has approximately 60 billion dosage forms manufactured annually and serves 150 countries globally.

Differentiator

Problem solved

Functional benefit

Brands

  • Aurohealth: Over the counter products division
  • Auro Vaccines
  • Aurobindo USA-BluePoint
  • Acrotech Biopharma

Products and services

  • Generic Pharmaceuticals Portfolio A broad line of AB-rated generic pharmaceutical finished dosage forms covering therapeutic categories such as antibiotics, antivirals, respiratory, hematology, cardiovascular, and central nervous system conditions, sold to national wholesalers and retail pharmacy chains.
  • Active Pharmaceutical Ingredients (APIs) More than 250 active pharmaceutical ingredient products including anti-infectives, peptides, biosimilars, vaccines, and polymers, manufactured across 17 API facilities for internal formulation use and external customers.
  • Aurovela Oral Contraceptives Generic oral contraceptive product line marketed as AB-rated equivalents to Loestrin products, indicated for pregnancy prevention.
  • Mili and Tri-Mili Oral Contraceptives Oral contraceptive product line of AB-rated generic equivalents to Ortho Cyclen and Ortho Tri-Cyclen; Mili for pregnancy prevention and Tri-Mili additionally indicated for moderate acne vulgaris.
  • Zumandimine and Lo-Zumandimine Oral Contraceptives Oral contraceptive product line of AB-rated generic equivalents to YASMIN and YAZ; Lo-Zumandimine additionally indicated for premenstrual dysphoria disorder symptoms and moderate acne.
  • Atazanavir Capsules AB-rated generic equivalent of REYATAZ atazanavir capsules available in 100 mg, 150 mg, 200 mg, and 300 mg strengths, indicated in combination with other antiretrovirals for HIV treatment.
  • Sildenafil Citrate Tablets AB-rated generic equivalent to VIAGRA sildenafil citrate tablets in 25 mg, 50 mg, and 100 mg strengths for the treatment of erectile dysfunction.
  • Oncology Injectable Portfolio (Acrotech Biopharma) Branded specialty oncology injectable product portfolio (including Marqibo and Khapzory) held through wholly-owned subsidiary Acrotech Biopharma LLC, serving US specialty distribution channels for cancer treatment.
  • UB-612 COVID-19 Vaccine Multitope peptide-based COVID-19 vaccine candidate licensed from COVAXX for development, commercialization and manufacturing for India and UNICEF markets, with initial 220 million dose capacity.
  • Cephalexin For Oral Suspension USP AB-rated generic equivalent to Keflex for Oral Suspension in 125 mg/5 mL and 250 mg/5 mL strengths, indicated for respiratory tract infections, otitis media, skin/skin structure infections, bone infections, and genitourinary tract infections.
  • Tofacitinib Tablets AB-rated generic equivalent to Xeljanz Tablets in 5 mg and 10 mg strengths, indicated for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
  • Eluxadoline Tablets AB-rated generic equivalent to Viberzi Tablets in 75 mg and 100 mg strengths, indicated for irritable bowel syndrome with diarrhea (IBS-D).
  • Canagliflozin Tablets AB-rated generic equivalent to Invokana Tablets in 100 mg and 300 mg strengths, indicated as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus.
  • Pirfenidone Capsules USP AB-rated generic equivalent to Esbriet Capsules in 267 mg strength, indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
  • Glycerol Phenylbutyrate Oral Liquid AB-rated generic equivalent to Ravicti Oral Liquid at 1.1 grams per mL, indicated as a nitrogen-binding agent for the chronic management of urea cycle disorders (UCDs).
  • Dapagliflozin Tablets AB-rated generic equivalent to Farxiga Tablets in 5 mg and 10 mg strengths, indicated as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus.
  • Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets AB-rated generic equivalent to Xigduo XR Tablets available in four strengths, indicated as adjunct to diet and exercise for type 2 diabetes when both dapagliflozin and metformin are appropriate.
  • Cefixime Capsules AB-rated generic equivalent to Suprax Capsules in 400 mg strength, indicated for urinary tract infections, pharyngitis, acute exacerbations of chronic bronchitis, and uncomplicated gonorrhea.
  • Clindamycin Phosphate Gel USP AB-rated generic equivalent to Cleocin T Gel at 1% strength, indicated for the topical treatment of acne vulgaris.
  • Citalopram Capsules AB-rated generic equivalent of Citalopram Capsules in 30 mg strength, indicated for the treatment of Major Depressive Disorder (MDD) in adults.
  • Siponimod Tablets AB-rated generic equivalent to Mayzent Tablets in 0.25 mg, 1 mg, and 2 mg strengths, indicated for the treatment of relapsing forms of multiple sclerosis.

Quantifiable outcome

  • 60 billion+ dosage forms manufactured in FY25
  • +2 more outcomes

Companies that use Aurobindo Pharma USA, Inc.

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Aurobindo Pharma USA, Inc. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Aurobindo Pharma USA, Inc. partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

  • COVAXXflagshipStrategic or Co-development Partner · 24 December 2020Aurobindo Pharma entered exclusive license agreement with COVAXX to develop, commercialize and manufacture UB-612 COVID-19 vaccine for India and UNICEF. Aurobindo has capacity to manufacture 220 million doses initially with plans to expand to 480 million doses by June 2021. UB-612 is the first multitope peptide-based vaccine candidate.
  • Dispensary of HopecoreGTM or Marketing PartnerAurobindo became partner to Dispensary of Hope in 2012. In 5 years, donated 3,736,413 doses of medicine. Donated products distributed to federally qualified health centers, free clinics, charitable pharmacies serving uninsured patients at or below 200% of Federal Poverty Guidelines.
  • CitiHopecoreGTM or Marketing PartnerPartnership from 2013-2016 provided critically needed medicines to qualified healthcare institutions for over 333,000 patients globally, including Dominican Republic, Uganda, and Malawi. Medicines treated infectious and chronic diseases including bacterial infections, diabetes, hypertension, migraine, and depression.
  • Brother's Brother FoundationcoreGTM or Marketing PartnerOngoing support of Brother's Brother Foundation for life-saving treatments. Pharmaceuticals donated to continents across 19 countries including Guatemala, Haiti, Ghana, Nigeria, Philippines, Uganda, Dominican Republic, Cameroon, Peru, Nicaragua, Honduras, Costa Rica, Malawi, Kenya, Central African Republic, India, Panama, Ecuador, and Vietnam.
  • Lannett Company LLCflagshipStrategic or Co-development PartnerFTC-approved acquisition of Lannett Company LLC for $250 million cash-free, debt-free transaction. Adds Seymour, Indiana manufacturing facility with approximately 4 billion doses annual capacity. Expands portfolio in complex generics and non-opioid controlled substances. Expected to close June 2026.
  • Quagen PharmaceuticalsminorOthersAs condition of FTC approval for Lannett acquisition, Aurobindo required to divest four generic pharmaceutical products to Quagen Pharmaceuticals to prevent market power consolidation in specific drug markets.
  • Spectrum PharmaceuticalsflagshipStrategic or Co-development PartnerAcrotech Biopharma LLC, wholly-owned subsidiary of Aurobindo Pharma USA, acquired portfolio of seven branded oncology injectable products from Spectrum Pharmaceuticals. Transaction valued at $160 million upfront plus up to $140 million in milestones. Expected to generate $100 million revenue in first 12 months.

Scale indicators12 records

Recent moves8 records

Expansion highlights4 records

Aurobindo Pharma USA, Inc. competitors and assessment

Company assessment

Broad incumbents

  • Endo International: Specialty and generics pharmaceutical company with US-focused operations across sterile injectables, generics, and branded specialty products. Comparable in US distribution and complex generics ambitions similar to Aurobindo's Lannett integration plans.

Direct peers

  • Teva Pharmaceutical Industries: The world's largest generic pharmaceutical manufacturer with an extensive US generics portfolio across oral solids, injectables, and specialty categories. Teva competes head-to-head with Aurobindo in distributing generic pharmaceuticals to US wholesalers and retail chains.
  • Dr. Reddy's Laboratories: India-headquartered generics and biosimilars manufacturer with a US commercial presence. Comparable in product mix (oral solids, injectables, biosimilars), India-to-US integration, and ANDA-driven revenue model.
  • Cipla: Major India-based generic pharmaceutical manufacturer with US operations and a broad portfolio of oral solids, injectables, and respiratory medications. Comparable as another vertically integrated Indian generic exporter serving the US market.
  • Sun Pharmaceutical Industries: India-based global generic pharmaceutical company with a large US subsidiary (Sun Pharma Global FZE / Taro). Comparable to Aurobindo as an Indian-headquartered generic exporter with US FDA-approved manufacturing and broad US distribution through wholesalers.
  • Lupin Pharmaceuticals: India-headquartered generic manufacturer with significant US presence in oral solids, injectables, and complex generics. Comparable to Aurobindo in targeting ANDA-rich therapeutic areas and supplying US national wholesalers.
  • Sandoz (Novartis): Global leader in off-patent medicines, including generics and biosimilars, with a major US generics business across oral solids, injectables, and complex generics. Directly comparable to Aurobindo's vertically integrated generics model and ANDA-driven US growth strategy.
  • Zydus Lifesciences: India-headquartered pharmaceutical company with US generics business and a vertically integrated API-to-finished-dose manufacturing model. Comparable in geographic origin, product mix, and ANDA-driven US growth strategy.
  • Viatris (formerly Mylan): Large diversified generics and specialty manufacturer with significant US footprint across oral solids, injectables, and complex generics. Viatris's broad portfolio, ANDA pipeline, and national wholesaler relationships mirror Aurobindo's competitive position in the US market.
  • Apotex: Canadian-based privately held generic pharmaceutical manufacturer with a substantial US generics business. Comparable as a privately held, vertically integrated generics competitor distributing through US wholesalers and retail chains.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Aurobindo Pharma USA, Inc. social profiles

Digital presence

Aurobindo Pharma USA, Inc. compliance and trust

Trust signal

Compliance2 records

Aurobindo Pharma USA, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aurobindo Pharma USA, Inc. leadership team

Management profile

Number of profiles

Profiles4 records

Aurobindo Pharma USA, Inc. subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Aurobindo Pharma USA, Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aurobindo Pharma USA, Inc. M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aurobindo Pharma USA, Inc.

What does Aurobindo Pharma USA, Inc. do?

Aurobindo Pharma USA manufactures and distributes a broad line of generic pharmaceutical products including oral solids, topicals, injectables, ophthalmics, and inhalations, supported by a vertically integrated supply chain that spans API production (17 facilities, 250+ API products), formulation, manufacturing, automated packaging, and warehousing/distribution (567,000 sq ft, 40,000 pallet capacity). The company sells exclusively through national wholesalers, retail pharmacy chains, and authorized distributors, and also markets branded specialty products such as oncology injectables through subsidiary Acrotech Biopharma and women's health products.

Is Aurobindo Pharma USA, Inc. a public or private company?

Aurobindo Pharma USA, Inc. is a private company. It is classified as corporate owned and is currently operating.

When was Aurobindo Pharma USA, Inc. founded?

Aurobindo Pharma USA, Inc. was founded in 1994. It employs 1,001 to 5,000 people.

Where is Aurobindo Pharma USA, Inc. based?

Aurobindo Pharma USA, Inc. is headquartered in East Windsor, United States, in the North America region.

How does Aurobindo Pharma USA, Inc. make money?

One revenue line is on record: generic Pharmaceutical Sales.

Who are Aurobindo Pharma USA, Inc.'s main competitors?

Endo International is listed as a broad incumbent. Direct peers are Teva Pharmaceutical Industries, Dr. Reddy's Laboratories, Cipla, Sun Pharmaceutical Industries, Lupin Pharmaceuticals, Sandoz (Novartis), Zydus Lifesciences, Viatris (formerly Mylan) and Apotex.

Does Aurobindo Pharma USA, Inc. have an API?

No public API is recorded for Aurobindo Pharma USA, Inc..

What industry is Aurobindo Pharma USA, Inc. in?

Aurobindo Pharma USA, Inc.'s product category is Generic Pharmaceuticals Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAG, Generic APIs & Intermediates (Active Ingredients). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireDiscolored Tablets Prompt Second Recall of Amazon-Brand Acetaminophen From the Same Manufacturer in About 16 MonthsAmazon Basic Care Extra Strength acetaminophen caplets were recalled from Aurobindo Pharma USA after consumer complaints of discolored tablets. The recall covers 112,932 bottles across 200-, 500-, and 1,000-count sizes, with no adverse health events reported. The cause of discoloration has not been disclosed.YahooOver 112,000 Bottles of Popular Pain Reliever Recalled Nationwide After Consumer ComplaintsAurobindo Pharma USA initiated a nationwide recall of Amazon Basic Care Extra Strength Acetaminophen on September 18 after consumer complaints of discolored tablets. The recall affects 112,000 bottles across three sizes, with the FDA classifying it as Not Yet Classified. Consumers are advised to contact a pharmacist for guidance.Business StandardAurobindo Pharma USA Inc. completes acquisition of LannettAurobindo Pharma USA Inc., a wholly owned subsidiary of Aurobindo Pharma, has completed its acquisition of Lannett Company, Inc. following U.S. Federal Trade Commission approval on June 18, 2026, with the transaction becoming effective on June 29, 2026. Lannett has become a wholly owned subsidiary of APUSA and will operate as Lannett Company LLC. The integration process will commence immediately with emphasis on uninterrupted medication access, maintaining partner relationships, and supporting employees through the transition.LinkedInAurobindo Pharma USA, Inc.Aurobindo Pharma USA, Inc. conducted an internal employee contest to name their warehouses, with staff voting on the final names from shortlisted entries selected by a diverse panel. The company's existing large Distribution Centre has been renamed 'Pacific', while their new 175,000-square-foot warehouse has been named 'Atlantic'. The initiative was described as reflecting company values of collaboration and workplace culture.Financial ExpressAurobindo Pharma to close $250-million Lannett acquisition by June-end after FTC nodAurobindo Pharma USA has received clearance from the US Federal Trade Commission to acquire Pennsylvania-based generic pharmaceutical company Lannett Company for $250 million on a cash-free, debt-free basis, with deal closure expected before the end of June. The acquisition brings Aurobindo a US-based manufacturing facility in Seymour, Indiana with capacity to scale to approximately 4 billion doses annually, along with expertise in complex non-opioid controlled substances. Aurobindo stated the transaction is expected to be immediately accretive to group earnings per share, with anticipated cost efficiencies, SG&A synergies, and operational integration benefits.AInvestAurobindo Pharma - obtains US FTC approval for Lannett acquisitionAurobindo Pharma USA Inc., the U.S. subsidiary of Aurobindo Pharma Ltd., has obtained FTC approval for its acquisition of Lannett Co., Inc., a U.S.-based producer of complex generic pharmaceuticals. The deal, valued at approximately $250 million on a cash-free, debt-free basis with an enterprise value of 5.5x EBITDA, will give Aurobindo access to Lannett's 425,000-square-foot cGMP manufacturing facility in Seymour, Indiana, with annual production capacity of 3.6 billion dosage units. Lannett reported LTM revenue of $306 million with expected EBITDA margins of approximately 15%, and the acquisition supports Aurobindo's strategy to expand its U.S. manufacturing footprint and diversify into higher-value therapeutic segments amid reshoring trends.AInvestAurobindo Pharma gets FTC nod to buy Lannett businessAurobindo Pharma USA Inc., the U.S. subsidiary of Aurobindo Pharma Ltd., has received FTC approval to acquire Lannett Co., Inc., a U.S.-based generic pharmaceutical manufacturer, for approximately $250 million on a cash-free, debt-free basis. The deal will grant Aurobindo full ownership of Lannett's 425,000-square-foot cGMP manufacturing facility in Seymour, Indiana, with annual production capacity of about 3.6 billion dosage units, while Lannett reported LTM revenue of $306 million with expected EBITDA margins of approximately 15%. The acquisition aligns with Aurobindo's strategy to expand its U.S. manufacturing footprint and diversify into higher-value therapeutic segments, reflecting broader reshoring pharmaceutical manufacturing trends amid regulatory and tariff pressures.Atlanta Journal-ConstitutionDrug recall: Mirtazapine may have wrong strength on labelAurobindo Pharma USA voluntarily recalled Mirtazapine bottles labeled 7.5 mg that may contain 15 mg tablets. The FDA warns that higher-than-expected doses increase risks of sedation, agitation, tremor, and falls in the elderly.BioWorldAurobindo Pharma strikes $1B deal for parts of Sandoz generics portfolioAurobindo Pharma USA Inc. has agreed to acquire a portfolio of dermatology and generic oral medicines from Sandoz Inc., the generics division of Novartis AG, for up to $1 billion. The deal includes an upfront payment of $900 million plus up to $100 million in potential earn-outs, adding approximately 300 products and U.S.-based commercial and manufacturing capabilities to Aurobindo's portfolio. Sandoz is divesting these assets as it pursues growth amid increasingly challenging forces in the generics space.PR NewswireNatrol® Introduces Three New Innovative Products to Support Beauty and Anti-Inflammatory NeedsNatrol LLC, a leading U.S. vitamin and supplement manufacturer based in Chatsworth, California, introduced three new products—Natrol Skin, Hair & Nails, Natrol Biotin Plus, and Natrol Extra Strength Turmeric—in May 2016. This marks the company's first product launch since being acquired by Aurobindo Pharma USA Inc., with the new products featuring novel ingredients such as clinical strength lutein in beauty supplements and CurcuWIN-enhanced turmeric. The products are being distributed through select retailers including Walgreens and Sprouts, as well as other health food retailers nationwide.